I must hold too but I sure have been getting clobbered with holding these far too long. To this day I see a new bright star so I decide to hold and as it seems I lose again?
...I know I can go on welfare and do better 🤣
Think it took Dent seven years to get NEO moving, not that it has anything in common with HL. At .03 don't see any point in taking an 85% loss, i will continue to hold and hope for a miracle.
No doubt we (HLYK) are at the bottom end of the rope while Dr. Dent and O' Leary are holding the rope. When and if they let go we will die however, they will end up with business as usual and continue the medical businesses without the public company. I see very little hope for us in the direction we are headed and to change directions at this point would most likely require a reverse split. If you look way back in the history of NEO you can see that reverse split. Dr. Dent seemed to think HLYK has more potential than Neogenomic Corporation but wonder what he thinks now? He seems to be very wrong in view of our present position/condition which royally sucks. Look at the years that have past.
It just doesn't look good and believe Dr. Dent is in transition with HLYK as we can't continue with a mom and pop business and stay invested. I'm sure he is fully aware that change is needed badly but what direction and at what cost? Dent will end up with the medical operations as he did when he started Pre- NeoGenomic.
This thing is done. Whatever happens from here won't be in our favor you can bet on that. Just my opinion.
They really haven't come up with anything unique,but at least they aren't selling snake oil.
I keep looking at your post and not saying a word but thinking I hope we rise to that level for you to break even prior any possible RS. I still have my money on Dent but just can't figure out how he will pull a rabbit out of the hat at this level and present speed. It seem far too many have walked this way in technology and since I have a good grasp on patents, patent infringement and so forth I'm shaking my head and waiting like a few others. No doubt we sincerely have concrete management but a questionable forward path involving a mom and pop medical business.
Holding over 400k @ .29. It went to .20 awhile back shoulda dumped and taken a mild beating but i never learn. Hopin they have one more run in them and i'm with ya.
I was able to dump 76,000 shares at .065 a few weeks ago. Now it can't even get back to that lol. I am done here too. hoping for some miraculous jump to .12-15 and I will be gone. I don't think these guys have a clue and they are living off of past money. I am at peace here 😀
https://www.flightaware.com/photos/view/12176-abb8b4d21b0342cf8f807dc02b182ca7b9e76e23 I'm just killing time anyways this is Dr. Dent's actual plane. Dr. Dent knows how to get around when he needs to.
I use FlightAware for tracking jets and actually tracked my wife flying in a B737M 8 from East Coast to PHX last Monday, anyways it is a nice flight tracker. Control tower sites and software are at hand and also cool to listen to.
A customizable avatar for whatever you choose to identify as that day..winner. Closes red day after a PR with A.I. in it..this company died two years ago.
Now I'm only going to place this link referencing the trademark in which use the following number 90849055 and dig as you please. https://tsdr.uspto.gov/
As for the recent press release my hope is that Dr. Dent is working with one of the following Algorithm Engineers.... John M. Ganci Jr., Martin Keen or Jeremy Fox. There is no way that Dr. Dent would be able to merge the needed algorithm himself, not a chance in a million years. I am also in hopes that he is pursuing both provisional and non provisional ARI patent mixes. Another need if he is really thinking big time is a fact that he must also apply for an International Patent but down deep realistically he/we might be better served to license patents from other players. I mean we are years behind others. We also since our 10-k filing for 2022 have fallen in what is stated from O'Leary/Dr. Dent material weakness in Internal controls. Now how much deferring of and moving figures around might help we need a break or infusion of money. We can only think positive just so long. With a proven Algorithm Engineer they would know what they can mix and develop into the patent so it doesn't get denied from the USPTO as being just another Algorithm patent application. As this moves HLYK forward into the field of vision from other existing AI patent players and that is when infringement ears start to open and take notice. This is why it is so important for the patent engineering process and patent legal team.
Key Features of ARI
ARI’s key features include the following:
Interactive Medical Profile Creation: ARI will enable users to interactively create their medical profiles within the HealthLynked Network. Patients can converse with ARI as if they are speaking to a nurse or doctor, making the data input process more intuitive and engaging.
Multilingual Capabilities: Recognizing the diverse linguistic needs of patients worldwide, ARI is equipped to converse in multiple languages, ensuring that language is never a barrier to quality healthcare.
Customizable Avatar: To enhance the user experience, ARI offers a customizable avatar feature. Patients can choose the gender, ethnicity, and appearance of their ARI avatar, ensuring a more personalized and comfortable interaction. Whether you prefer speaking to a male or female avatar, or one that reflects your ethnicity, ARI has got you covered.
Integration with HealthLynked Network: Seamlessly integrated with the HealthLynked Network, ARI ensures a comprehensive view of a patient’s medical history, optimizing healthcare recommendations.
This is positive news Nice post, initially this sounds positive depending how it was written and the various avenues it may work/merge with the first patent and of course future patents. My hope is that Dr. Dent refined the first patent since and incorporated new writings.
$HLYK HealthLynked Announces Patent Filing for ARI: A Revolutionary AI-Powered Healthcare Interface
HealthLynked Announces Patent Filing for ARI: A Revolutionary AI-Powered Healthcare Interface
NAPLES, Fla., Oct. 3, 2023 /PRNewswire/ -- HealthLynked Corp. (OTCQB: HLYK) is thrilled to announce a patent filing for its innovative artificial intelligence (AI) program, ARI (Augmented Real-time Interface). This strategic move highlights HealthLynked's dedication to spearheading advancements in the healthcare domain. With the patent filing in place, HealthLynked expects to launch ARI before the end of 2023, aiming to redefine patient and healthcare provider interactions.
The Importance of Patient Engagement and Updated Medical Information
Engaging patients in their healthcare journey and ensuring that their medical information is up-to-date are critical components in delivering the best possible medical care. Historically, the healthcare system has struggled with the seamless exchange of medical information among healthcare providers. Traditional electronic medical records (EMRs) have been primarily designed with doctors and hospitals in mind, leading to fragmented systems that often compete for clientele rather than collaborate. This competition has resulted in a lack of willingness to integrate, leaving patients with disjointed medical records scattered across various platforms or portals.
HealthLynked stands out in this landscape as the only patient-focused medical record system that prioritizes user control and real-time medical information updating. By placing patients at the center of their healthcare experience, HealthLynked empowers patients to take charge of their health, ensuring that their medical data is accurate, comprehensive, and easily accessible to all of their healthcare providers.
Dr. Michael Dent, CEO of HealthLynked, commented, "AI stands at the forefront of technological advancements poised to dramatically reshape our lives in the coming decades. Its potential is vast and its implications profound. Nowhere is this transformative power more evident than in the realm of healthcare. As we navigate the complexities of modern medicine, AI offers the promise of personalized care, predictive diagnostics, and a level of patient engagement previously unimagined. As we stand on the cusp of this new era, it's clear that the fusion of AI with healthcare will not only redefine patient care but also pave the way for a future where healthcare is more accessible, efficient, and tailored to individual needs."
It was Dr. Dent who started NeoGenomics on its way with new ideas but as I said prior it was Douglas VanOort that put the company into orbit. I feel with H;LYK we have very little chance if any of the success that NeoGenomics had yet Dent said different a couple of years ago, hey what happened to that Dr. Dent? I feel we are too far behind everyone else and our technology seems not too forth coming meaning who wants it plus I don't need to address our patent again but do hope if Dr. Dent is seriously moving forward with more than a mom and pop business that is in retirement mode that he gains drastic help involving refining our patent in a huge way.
We see very little happening in the AI area as we had hoped so what gives? We can't move into any direction but no doubt that is what we may need to do. We see our share price at 4 cents again and it appears Dent/O'Leary must modify whatever plan of action/direction the company must move in within the next two months if not sooner.
We have some news so what the heck at least we are still breathing
HealthLynked Achieves Key Milestone with Final $300,000 Payment from Sale of ACO Health Partners
NAPLES, Fla., Sept. 5, 2023 /PRNewswire/ -- HealthLynked Corp. (HLYK), a leader in the global healthcare network industry, is pleased to announce the successful completion of cash targets to date related to its January 2023 sale of ACO Health Partners ("AHP"). The company received a $300,000 payment, marking a 100% success rate in enrolling existing and new physician practices into Palm Beach Accountable Care Organization ("PBACO"), managed by PBACO Holding, LLC ("PBA").
Since the sale of AHP, HealthLynked has received a total of $3.25 million, comprised of an initial $750,000 from the sale and an additional $2.5 million in participation-based consideration. The payments represent the maximum amount of cash consideration to date that HealthLynked was eligible to receive under the sale agreement. The company is also expecting a further $500,000 in future savings in October 2024.
In line with the sale agreement, HealthLynked is set to receive net proceeds, including allocation of expenses, from Medicare Shared Savings attributed to AHP's performance in 2022. Current projections estimate these proceeds will exceed $1.0 million, with payments anticipated in early October 2023.
Furthermore, HealthLynked has secured a six-month extension from PBA for the possibility of earning equity in the event of PBA's future initial public offering ("IPO"). Initially slated to be completed by August 1, 2024, the deadline has been extended until February 1, 2025. Should PBA go public, HealthLynked will receive shares corresponding to AHP's 2021 earnings, times the EBITDA multiple used to value PBA's IPO shares.
George O'Leary, HealthLynked's Chief Financial Officer, commented, "Our collaboration with Palm Beach ACO has been outstanding, and we are excited about the prospects of continuing this successful partnership for years to come."
HealthLynked Corp. is revolutionizing healthcare by bridging the gap between patients and providers through its innovative, cloud-based platform. The HealthLynked Network aims to improve healthcare outcomes by facilitating the seamless exchange of medical information, empowering patients to take control of their healthcare journey.
For Patients: Free of charge, members can store vital medical information such as medications, allergies, past surgeries, and personal health records in one secure, online location. The platform allows easy connection with healthcare providers, both current and future, to ensure a more coordinated healthcare experience.
For Providers: Providers can join the network to gain access to HealthLynked's patented patient access hub, known as "PAH," which offers valuable patient analytics. The system also includes a suite of marketing tools designed to improve patient retention and facilitate better communication. Providers benefit from streamlined online appointment scheduling and can even fill last-minute cancellations using the platform's real-time appointment scheduling feature.
Membership and Costs
For Patients: Patients can sign up for HealthLynked at no cost, but upgraded services are only available to paid members. Free membership does not include advanced features such as access to HealthLynked's medical record management team, patient scheduling, and nurse onboarding services.
For Providers: Doctors and practices can claim their profile for free, allowing basic presence within the HealthLynked Network. Free profiles do not include access to premium services such as marketing tools, preferred placement within the network, patient record sharing, and other cost-saving features.
For Premium Members: Preferred providers can access HealthLynked's full range of services by paying a monthly fee, which includes marketing tools, priority placement within the network, and enhanced patient engagement features.
To learn more about how HealthLynked is changing the healthcare landscape, visit www.healthlynked.com. Stay connected with us on Twitter, Facebook, Instagram, and LinkedIn.
Yes, we look pretty bleak to say the least...just a mom and pop business so it appears Dr. Dent is in retirement mode.
HealthLynked Announces Steady YoY Revenue Increase for Q2 & H1 2023, Highlighting Significant Net Income Boost
Naples, Fla. -- August 15, 2023 -- InvestorsHub NewsWire -- HealthLynked Corp. (OTCQB: HLYK), a leading online healthcare network connecting patients, doctors, and medical data, provides an integrated platform designed for real-time collaboration and data exchange. At the heart of this is their patient-centric electronic medical record network, underscoring the pivotal role of patient engagement in healthcare decisions. Committed to redefining healthcare delivery, HealthLynked focuses on superior efficiency, precision, and affordability. Today, the company announced its financial reporting for the second quarter and first half ending June 30, 2023.
Q2 2023 Highlights:
Revenue: 9% YoY growth, reaching $1.70 million, up from Q2 2022's $1.56 million.
Primary Drivers of Revenue Growth: A notable 13% YoY increment from Functional Medicine offerings, complemented by contributions from Aesthetics Treatment Centers (acquired in May 2022).
Operating Loss Reduction: A remarkable 48% drop, moving from Q2 2022's $1.53 million to a more streamlined $0.80 million in 2023. This achievement is attributed to a blend of revenue augmentation and a targeted 34% YoY decrease in selling, general, and administrative expenses.
Net Loss Reduction: 37% decrease, tapering the net loss from $1.59M to $1.00M.
H1 2023 Highlights:
Revenue: 12% YoY increase, coming in at $3.46 million, compared to H1 2022's $3.09 million.
Operational Losses: Trimmed by 38%, declining from H1 2022's $2.98 million to $1.85 million in H1 2023, reflecting the combined impact of the 12% revenue growth and a 25% YoY cut in operational expenses.
Special Recognition: A gain of $2.67 million was recognized related to the divestiture of ACO Health Partners in January 2023.
Net Income: Net income of $0.45 million was reported, a positive shift from the net loss of $2.76 million observed in H1 2022, driven by the gain from the sale of ACO Health Partners coupled with revenue and cost improvements.
CEO, Dr. Michael Dent, expressed, "Our dedication to transforming the healthcare landscape remains unwavering. With a keen focus on streamlining operational efficiencies and nurturing consistent revenue growth, we've forged significant milestones in fortifying our financial trajectory. The inauguration of our premium offerings for patient members doesn't just broaden our service spectrum; it amplifies the essence of value we offer to our community. Central to this evolution has been the establishment of strategic alliances, each reinforcing our enduring mission: to deliver unparalleled healthcare at an affordable price point. Every initiative, every endeavor underscores our encompassing vision – to redefine and democratize quality healthcare, making 'better healthcare for less' a tangible reality for all."
George O'Leary, HealthLynked's Chief Financial Officer, added, "From a revenue perspective, we continue our strong quarterly and year to date revenue growth. We continue to strengthen our collaborative ties with Palm Beach ACO. Lastly, our year-to-date net income of $0.45 million compared to a net loss of $2.76 million in the previous year speaks to the work we have been doing to create more shareholder value."
HealthLynked Corp. provides a solution for both patient members and providers to improve healthcare through the efficient exchange of medical information. The HealthLynked Network is a cloud-based platform that allows members to connect with their healthcare providers and take more control of their healthcare. Members enter their medical information, including medications, allergies, past surgeries, and personal health records, in one convenient online and secure location, free of charge. Participating healthcare providers can connect with their current and future patients through the system. Benefits to in-network providers include the ability to utilize the HealthLynked patent-pending patient access hub "PAH" for patient analytics. Other benefits for preferred providers include HLYK marketing tools to connect with their active and inactive patients to improve patient retention, access more accurate and current patient information, provide more efficient online scheduling, and to fill last-minute cancelations using the Company's "real-time appointment scheduling" all within its mobile application. Preferred providers pay a monthly fee to access these HealthLynked services. For additional information about HealthLynked Corp., please visit www.healthlynked.com and connect with HealthLynked on Twitter, Facebook, Instagram, and LinkedIn.
Forward-Looking Statements & Risk Factors
Forward-Looking Statements in this press release, which are not historical facts, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Our actual results, including as a result of any acquisitions, performance, or achievements may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue," "likely," "will," "would" and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by our management, and us are inherently uncertain. We caution you not to place undue reliance on any forward-looking statements, which are made as of the date of this press release. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. Certain risks and uncertainties applicable to our operations and us are described in the "Risk Factors" section of our most recent Annual Report on Form 10-K and in other filings we have made with the U.S. Securities and Exchange Commission. These reports are publicly available at www.sec.gov.
Director of Investor Relations
+1 (800)-928-7144, ext. 123
Well, whatever Dent is thinking he's certainly not communicating it to his shareholders, all 26 of us.
Probably but timing issues among other thoughts seem to happen. As for our darling Sabrina she would only be good to possibly help jump start HLYK since I view her as self serving, far too young to be satisfied very long without moving into being the star of everything but who knows what Dent is thinking?
Regurgitated from a low level postion in house,replaces equally wothless Sabrina Katz to trailblaze new paths fwd for HL.
I missed this PR back on 8/1/23
HealthLynked Corp. Names Wall Street Veteran Mike Paisan to Strategic Investor Relations Role
NAPLES, FL -- August 1, 2023 -- InvestorsHub NewsWire -- HealthLynked Corp. (HLYK), a global healthcare network specializing in care management for its members, announced the appointment of Mike Paisan as Director of Investor Relations and Strategic Partnerships. HealthLynked, which employs innovative healthcare technologies to link patients, doctors, and medical data, is committed to enhancing healthcare services worldwide.
In this new role, Mike will act as a dedicated liaison between the company and its investors, providing regular updates about the company's progress, answering shareholder queries, and keeping shareholders informed about the transformative work HealthLynked is doing in the healthcare sector through its technology.
As part of improving investor relations, Mike will also implement a series of enhancements, including updating the investor website for better accessibility and user experience.
Mike joined HealthLynked as a Business Analyst in September 2021, and his extensive research has played a pivotal role in the company's strategic decisions. As an expert in competitor analysis and industry trends, Mike has equipped HealthLynked with crucial insights for informed decision-making.
CEO Dr. Michael Dent commented, "Working with Mike has been a great experience. His in-depth research and understanding of the industry have helped us make more informed business decisions. It was a natural fit for Mike to take on the investor relations role as we continue to grow, and we are confident he will excel in this new position."
Mike's 20-year stint on Wall Street as a Sell-Side Equity Research Analyst has equipped him with invaluable expertise. His focus on large, publicly traded insurance companies, and his recognition by the Wall Street Journal as the “Best on the Street” analyst three times, attest to his analytical prowess.
I believe my average is higher not sure but do know it is because I would buy and sell this in order to gain more shares. We have experienced management which is good. My friends did warn me about Dent trying to break into the medicare area as it is super hard to stay alive being such a small company. As I said prior Dent has used his private companies doing the same hop scotch game and that is fine if it works for us shareholders. In any event dent protected himself as he will end up with the starting deck of cards one way or another. I still have hope but for something good to happen here and feel if nothing more we will exist as owning Dents medical operations and paying him and O' Leary as we just exist.
I wonder if Dan is still on board?
If we can't find (at least in my thinking) a new direction with a decent plan all the past puffing we all had seen involving Dr. Dent accomplishments will fade away into the sunset.
You gotta omit that having Dent/O"Leary is a damn good start but as for accomplishing what HealthLynked was to be I doubt....we need a new direction but how is that even possible with our backs pinned to the wall at least it seems that way!!
At this point i have written it off as another poor choice with an OTC and i certainlty should know better by now. That being said, it makes little sense to flush and there is that small % that they are just re inventing them selves and are coming up with an answer to profitability. Just can't see these two as typical snake oil CEO mgmt, they would have ripped the band aid off long ago and shuttered the biz. My average is.29 and it wouldn't take an earth shattering catalyst to get there,if only for a brief moment. You have to remember this thing has been off the radar for at least two years and there are very few shareholders..some new blood coming in and you just might be able to sell them your tickets.
If HLYK fails Dr. Dent doesn't just us shareholders along with HealthLynked Corporation. Dr. Dent covered his a$$ with massive millions of shares and you can't blame him I would do the same. The hope of AI was what he pushed and that doesn't look good. As for the patent that is so poorly written and I have no doubt that Dr. Dent knows this too. I should not talk about this area for a few reasons so I'll just clamp it about that.
Dr. Dent is good with ideas but not so much like involving NEO. Doug made that corporation fly.but I had high hope that Dr. Dent could make HLYK successful because it isn't a huge corporation yet allowing him to grow with the company. As for NEO Dent took the share price to $1.40-$1.60 as I recall and that is all.
I was so sadden when I did my in depth studies at the USPTO involving our patent.
Dr. Dent as most know here is to reward O'Leary for deals that he comes up with and those words kinda struck me like what is Dr. Dent doing is he just doing his medical practice and that other business from within his home or am I wrong?
I haven't checked to see if any new businesses have been initiated by Dr. Dent or O'Leary but will check in the next few days.
Lets hope they pull something out of their hat worth talking about. I do know Dr. Dent doesn't panic easily and works at his own speed so maybe all this will eventually work out for but short and long term traders and investors?
We will see what has been happening when they file their 10-Q in August.
So, does this company really have nothing? Spinning previous announcements that haven't fooled anybody.
I continue to watch large quantities of stock, 100K lots, trade at these low prices. I get it that someone is buying these but who is selling these? I can't imagine whoever is selling is any where close to breaking even.
Hell, I wanted to unload my position at $.20. Now I wonder if this ever sees $.10 again. Like I said before, I've been involved in two of these "Can't miss" OTC stocks, guess what...they both missed.
Do you guys see that Form 4? Is that stating that George is now buying warrants for a past loan? It actually sounds as if the loan transaction/warrant purchase was a few days ago? It sounds ...but yet these warrants "to" be purchased but has not transpired yet?...my thoughts also think we will see another filing from Dent in the same manner?
I just hope this isn't a new loan?
Sounds like a great place to work lol
This is an "Indeed" review but don't know if it is a true?
Currently work here and how they treat the staff is disgusting
App analyst (Current Employee) - Naples - May 4, 2023 Indeed Featured review
The management and turnover is appalling. Too many managers. I’ve never felt
more unstable in a job. No perks to working here. They treat us like a number.
All they see are dollar signs and the CEO and CFO are never on the same page.
The app doesn’t work and they try to trick people into using it. They say a
nurse is answering the app questions but it’s really someone with no medical
background. The place is spiraling and a complete disaster. I am currently
looking for a new job.
Pros - None. My coworkers are the only pro.
Cons - Too many managers. Micromanaged to the core.
Here's the one good thing. A.I. is the hottest buzzword on Wall St,Dent was pimping it when noone else was, at least in the med records field. Pretty much everyone that was in this two years ago has moved on,it's back to 2018 valuations( ask me how i know) IF they release just the right PR with a sprinkling of A.I. pixie dust, you may have a chance to sell this bag of poop on a spike to the next OTC dreamer , be ready with that sell button..
Certainly I can. Their CFO publicly stated in their 10Q's that they were going to uplist. For 6 months this was listed in their 10Q's and suddenly it wasn't.
Look, all OTC stocks are risky and shit, for lack of a better word. The company's that play the kind of game Healthlynk did, are the worst because they string you along with the carrot.
I don't know Dr. Dent from desk chair. He's not looking real smart to me right now and those who did private placements in the $.50 range and above, based on the nonsense George Forman posted about uplisting, make them look real scammy to me.
Then that did that horrible S-1 with Yorkton.
I was hoping to get to .20 and take my loss, now I don't know how this gets back to $.10.
Then why bother with any PR's of late/ Not like they are doing anythIng for the SP.
Several years back Dr. Dent tried to build a multi-faceted medical business and failed but this time it looks like HLYK will pay the price and Dr. Dent will just continue his medical business with his wife and a few others. You can't blame him for this type of structure in business.